Alaunos Therapeutics, Inc.
1.49 +0.00 (0.00%)
- Marktkapitalisierung
- $3.79M
- Volumen
- 5.69K
- Nächster Ergebnistermin
- Aug 14, 2025
Alaunos Therapeutics, Inc. (TCRT) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$17,09 | -$12,59 | -184.83% |
Kennzahlen
- Geld
- 1.26
- Marktkapitalisierung
- 3.79M
- Umsatz (TTM)
- 3K
- Nettogewinn (TTM)
- -4.12M
- -0.97
- -1.75
- n/a
- -2.48
- KBV (TTM)
- 2.75
- KUV (TTM)
- 1261.77
- Termin Quartalszahlen
- Aug 14, 2025
- Brief
- 1.7
- Volumen
- 5,688
- Ø Vol. (20D)
- 12,283
- Eröffnung
- 1.47
- Vortagesschluss
- 1.49
- Tagesspanne
- 1.47 - 1.49
- 52-Wk Range
- 1.47 - 4.59
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Alaunos Therapeutics, Inc.
Profil ansehen →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Branche Biotechnology
Sektor Healthcare
IPO Datum Aug 24, 2005
Mitarbeiter 1
Börse NasdaqCM
Tickersymbol TCRT
Website https://www.alaunos.com